^
    Back
    Association details:
    Biomarker:MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Zynlonta (loncastuximab tesirine-lpyl) (DNA replication inhibitor, CD19-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ICML 2021
    Title:

    177 | LOTIS 2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma

    Published date:
    06/09/2021
    Excerpt:
    145 pts with R/R DLBCL received ≥1 dose of Lonca....ORR for pts with double-/triple-hit DLBCL was 33.3%... After longer follow-up of pts in LOTIS 2, durable responses to Lonca continue to be observed in heavily pre-treated pts with R/R DLBCL.
    Trial ID:
    LOTIS-2